Evidence map›Paper›PMID 29247298›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018

Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide.

T D Htet, J A Eisman, G J Elder, J R Center

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues.Best practice & research. Clinical rheumatology · 2022
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

T D HtetDepartment of Endocrinology, St Vincent's Hospital, Sydney, Australia. thaw.htet@svha.org.au.
J A EismanDepartment of Endocrinology, St Vincent's Hospital, Sydney, Australia.
G J ElderDepartment of Endocrinology, St Vincent's Hospital, Sydney, Australia.
J R CenterDepartment of Endocrinology, St Vincent's Hospital, Sydney, Australia.
St Vincent's Hospital Sydney · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.

Indexed as

AgedBone Density Conservation AgentsCalcinosisConnective Tissue DiseasesDisease ProgressionHumansMaleOsteoporosisTeriparatideTomography, X-Ray ComputedBone Density Conservation AgentsTeriparatideDystrophic calcificationOsteoporosisTeriparatide

Identifiers

PMID29247298
OpenAlexW2773564078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.